Across TCGA pan-cancer cohorts, AURKAIP1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated AURKAIP1 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher AURKAIP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AURKAIP1 expression acts as an unfavorable survival marker.
SKCM and ESCA are the cancer types where AURKAIP1 Mutation most reproducibly stratifies survival.